UG

Usha Gupta

Director Director DIN 00642241
DIN 00642241 First appointment Apr 1993 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Apr 1993
Shareholding value β€’β€’β€’β€’ Premium profile

About Usha Gupta

Data last updated:

Usha Gupta was a Director at Lucent Biotech Limited (2005–2017) and Director at Ajanta Theatres Private Limited (from 1993). The companies operate in Pharma.

DIN 00642241
Primary Designation Director
Industry Pharma
First Appointment 01 Apr 1993
Oldest Company Age 48 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Lucent Biotech Limited U24232UP2005PLC029816
Director26 Apr 20052005₹70.00 Cr (FY 2025)Active
Ajanta Theatres Private Limited U92111UP1978PTC004530
Director01 Apr 19931978Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Ajanta Theatres Private Limited
Lucent Biotech Limited
Premium access

Shareholding and investment profile for Usha Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Usha Gupta

Usha Gupta was first appointed on 01 Apr 1993 as Director at Ajanta Theatres Private Limited. The most recent appointment on record is 26 Apr 2005 at Lucent Biotech Limited.

Usha Gupta held 2 earlier board appointments: Lucent Biotech Limited (Director, 26 Apr 2005 to 05 Sep 2017); Ajanta Theatres Private Limited (Director, from 01 Apr 1993).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available